TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female DEERS-eligible dependent military health care beneficiaries age 8 to 18 years old evaluated by Pediatric Gastroenterology service at WRAMC and are scheduled to undergo a colonoscopy between 1 Sep 2010 - 31 Dec 2011 and do not meet exclusion criteria.~Exclusion Criteria:~* Age less than 8 years or greater than 18 at time of procedure~* Colonic surgery including hemicolectomy, colectomy, ileostomy, or multiple abdominal surgeries.~* Oral aversion or other feeding disorder.~* Inability to drink large amount of liquids.~* Aspiration risk.~* Renal disease or pre-cleanout electrolytes outside normal range.~* Significant cardiovascular disease.~* Allergy to food coloring or polyethylene glycol 3350.~* Inpatient or emergency colonoscopy.~* Current nasogastric tube in place.~* Known Pregnancy. Urine pregnancy test will only be completed on day of colonoscopy for all females age 14 and older per current standard anesthesia protocols. There have been no known reported animal or human studies that report the fetal effects of using polyethylene glycol. Per FDA, it is labeled as a category C drug in pregnancy. However, two studies , have reported successful treatment of constipation during pregnancy using polyethylene glycol solutions and did not find any significant effects or safety issues

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Polyethylene glycol 3350 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Breast cancer participants scheduled to receive the AT regimen (doxorubicin/ docetaxel)~Exclusion Criteria:~* Participants may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-Blind Phase: Pegfilgrastim (Type: ACTIVE_COMPARATOR): Participants will receive pegfilgrastim 6 milligrams (mg), administered by subcutaneous (SC) injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/square meter (m\^2) and docetaxel 75 mg/m\^2 administered sequentially by intravenous (IV) infusion on Day 1 of treatment for up to four 21-day cycles.
- Double-Blind Phase: Neugranin 40 mg (Type: EXPERIMENTAL): Participants will receive neugranin 40 mg, administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 administered sequentially by IV infusion on Day 1 of treatment for up to four 21-day cycles.
- Open-Label Phase: Neugranin 40 mg (Type: EXPERIMENTAL): Participants will receive neugranin 40 mg, administered by SC injection once per chemotherapy cycle (approximately 24 hours after chemotherapy administration) for up to 4 cycles (each cycle length = 21 days). The chemotherapy regimen consists of doxorubicin 60 mg/m\^2 and docetaxel 75 mg/m\^2 administered sequentially by IV infusion on Day 1 of treatment for up to four 21-day cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of chronic spontaneous urticaria refractory to H1 antihistamine at the time of randomization~* Chronic spontaneous urticaria diagnosis for 6 months~Key Exclusion Criteria:~* Weight less than 20 kg~* Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria~* Evidence of parasitic infection~* Any other skin diseases than chronic spontaneous urticaria with chronic itching~* Previous treatment with omalizumab~* Contraindications to diphenhydramine~* History of anaphylactic shock~* History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study~* History of hypersensitivity to omalizumab or to drugs of similar chemical classes~* Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Omalizumab 300 mg (Type: EXPERIMENTAL): Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 12 week treatment period.
- Omalizumab 150 mg (Type: EXPERIMENTAL): Participants received omalizumab 150 mg subcutaneously every 4 weeks during the 12 week treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo subcutaneously every 4 weeks during the 12 week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemic or gout patients~* Serum urate level:~\>= 7.0mg/dL in patients with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL~Exclusion Criteria:~* Gouty arthritis within two weeks before start of study treatment~* Secondary hyperuricemia~* HbA1c: \>= 8.4%~* Uric acid-overproduction type in the classification of hyperuricemia~* History of, clinically significant cardiac, hematologic and hepatic disease~* Kidney calculi or clinically significant urinary calculi~* Hepatic dysfuction, or AST: \>=100 IU/L or ALT: \>=100 IU/L at the pre-examination~* eGFR: \< 30mL/min/1.73m\^2~* Systolic blood pressure: \>= 180 mmHg~* Diastolic blood pressure: \>= 110 mmHg

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FYU-981 (Type: EXPERIMENTAL): None
- Benzbromarone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of 5 and 10 Days Treatment With Penicillin Against Sore Throat Caused by Streptococci

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults, adolescents and children ≥ 6 years of age with verified streptococcal pharyngotonsillitis.~Exclusion Criteria:~* Signs of serious infection.~* Known hypersensitivity against penicillin.~* Chronic disease with effect on the immune response.~* Immunosuppressive treatment.~* Streptococcal tonsillitis within one month (relapse).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 days (Type: EXPERIMENTAL): Phenoxymethylpenicillin 800 mg x 4 for 5 days
- 10 days (Type: ACTIVE_COMPARATOR): Phenoxymethylpenicillin 1000 mg x 3 for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults,18 through 50 years of age, who were or might be routinely exposed to N. meningitidis cultures~Exclusion Criteria:~* Previous ascertained or suspected disease caused by N. meningitidis;~* Pregnancy or breastfeeding;~* History of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component;~* Any present or suspected serious acute or chronic disease~* Known or suspected autoimmune disease or impairment /alteration of immune function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 4CMenB (Type: EXPERIMENTAL): None
- MenACWY CRM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.~Exclusion Criteria:~* Subjects who have used bupropion (Zyban, or Wellbutrin) previously.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic HCV infected, male and non-pregnant/non-lactating females aged 18 years or older who are on dialysis for ESRD, including adults with HIV co-infection if they are suppressed on a stable, protocol-approved antiretroviral (ARV) regimen for ≥8 weeks prior to screening.~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RenalGuard System and Contrast Media

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>=18 years~2. Chronic kidney disease (estimated glomerular filtration rate \<=30 ml/min/1.72 m2) and/or~3. Risk score for contrast nephropathy ≥11 (according to the Mehran score; J Am Coll Cardiol 2004; 44: 1393-1399)~Exclusion Criteria:~1. Pregnancy~2. Heart failure (NYHA functional class III-IV)~3. Acute pulmonary edema~4. Acute myocardial infarction~5. Recent (\<=2 days) contrast media exposure~6. Patients enrolled in concomitant studies~7. Administration of theophylline, dopamine, mannitol and fenoldopam.~8. End-stage CKD (patients on chronic dialysis)~9. Systemic hypotension (systolic blood pressure \< 100 mg/dl).~10. Multiple myeloma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Systemic alone therapy group (Type: ACTIVE_COMPARATOR): Systemic alone therapy group will be treated by intravenous sodium bicarbonate plus NAC administration. Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. (9) The initial i.v. bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days. Additional NAC dose (1.2 g) will be administered i.v. during the procedure.
- RenalGuard System group (Type: EXPERIMENTAL): Prophylactic controlled hydration with saline (0.9%) plus N-acetylcystein (NAC; 6 g in total). In the RenalGuard group, an initial bolus (priming) of 250 ml will be administered. In case of left ventricular dysfunction (ejection fraction ≤30%) and/or unstable hemodynamic conditions the bolus will be reduced to 150 ml. Following the initial bolus, furosemide (0.25 mg/kg) will be administered in order to achieve the optimal urine flow (≥300 ml/h). The hydration will be continued throughout the duration of the procedure and will last 4 hours following the procedure. Additional doses of furosemide are allowed in case of decrease of urine flow \<300 ml/h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Homozygous for the F508del mutation (F/F)~* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* Clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Solid organ or hematological transplantation~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TEZ/IVA (Type: ACTIVE_COMPARATOR): Following a run-in period of 4 weeks with Tezacaftor (TEZ)/Ivacaftor (IVA), participants received TEZ 100 milligram (mg)/IVA 150 mg as fixed-dose combination (FDC) tablet in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the triple combination (TC) treatment period.
- VX-445/TEZ/IVA TC (Type: EXPERIMENTAL): Following a run-in period of 4 weeks with TEZ/IVA, participants received VX-445 200 mg/TEZ 100 mg/IVA 150 mg as FDC tablets in the morning and IVA 150 mg as mono tablet in the evening for 4 weeks in the TC treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anesthetic Efficacy of Intrauterine Lidocaine for Removal of a Lost Intrauterine Device

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~patients undergoing a minor gynecologic procedure for removal of a lost IUD.~Exclusion Criteria:~women with a history of cervical stenosis, known allergy to lidocaine, pregnancy, acute cervicitis

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have schizophrenia~* Patients must be clinically stable on antipsychotic medication~* Patients must be retrospectively judged by investigators, based on clinical interview and impression, to have been stable (with respect to their symptoms of schizophrenia) for at least 4 weeks entry into the study~* Patients must be an outpatient and have BPRS positive items scores of 4 or less to enter the study~* Female patients of childbearing potential must be using a medically accepted means of contraception.~Exclusion Criteria:~* Patients must not have participated in a clinical trial of another investigational drug, including olanzapine, within 1 month (30 days) prior to study entry.~* Female patients must not be pregnant or breast-feeding~* Patients must not be experiencing acute, serious, or unstable medical conditions other than schizophrenia~* Patients must not require concomitant treatment with any other medication with primarily central nervous system activity, including antidepressants, mood stabilizers, and anticonvulsants.~* Patients must not have a substance (except nicotine or caffeine) dependence within the past 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults from 18 to 80 years old with an estimated alcohol intake of:~  * 14 units of alcohol per week during the month before hospitalisation for men aged 18 to 64~ * 7 units of alcohol per week during the month before hospitalisation for women or men older than 65.~AND Intubated, ventilated with an expected duration of mechanical ventilation\> 24 hours at least~Exclusion Criteria:~* Hospitalization \> 7 days~* Baclofen administration before ICU admission (personal treatment or single administration)~* Pregnancy~* Porphyria~* Burned on ICU admission~* Personal treatment including Gamma-hydroxybutyric acid (Alcover/Xyrem)~* Recent stroke or subarachnoid haemorrhage or head trauma with radiological evidence~* Recent or old paraplegia or tetraplegia~* Cardiac arrest with resuscitation manoeuvres before or after ICU admission~* Contraindication to Enteral drug administration for longer than 24 hours~* Lack of social protection~* Hypersensitivity to Baclofen~* Coeliac disease~* Refractory epilepsy~* Dementia, schizophrenia, Bipolar disorder or severe depression.~* Parkinson's disease~* Health care limitation owing to pejorative prognosis~* Tracheotomy on ICU admission~* Patients under guardianship or trusteeship~* Patients already enrolled in interventional study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BACLOFEN (Type: EXPERIMENTAL): patient will receive baclofen caps
- PLACEBO (Type: PLACEBO_COMPARATOR): patient will receive placebo caps (lactose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic schizophrenic disorder, according to the Diagnostic and Statistical Manual of Mental Diseases, 3rd edition (DSM-III-R) criteria~* total score on the PANSS at study entry of \>=60 and \<=120~* physical and neurological examination and ECG findings and clinical hematology, biochemistry, and urinalysis test results within normal limits before study entry~* patients must be able to be hospitalized the first 3 weeks of the study, if possible.~Exclusion Criteria:~* Patients with mental disorders other than chronic schizophrenic disorder~* patients with clinically significant organic or neurologic diseases~* women who are pregnant or breastfeeding, and women of childbearing potential without adequate birth control measures~* patients with epilepsy~* history of alcohol or drug abuse history within the previous 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete